BR112013009276A2 - peptídeos de c18orf54 e vacinas incluindo os mesmos - Google Patents
peptídeos de c18orf54 e vacinas incluindo os mesmosInfo
- Publication number
- BR112013009276A2 BR112013009276A2 BR112013009276A BR112013009276A BR112013009276A2 BR 112013009276 A2 BR112013009276 A2 BR 112013009276A2 BR 112013009276 A BR112013009276 A BR 112013009276A BR 112013009276 A BR112013009276 A BR 112013009276A BR 112013009276 A2 BR112013009276 A2 BR 112013009276A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- c18orf54
- same
- vaccines
- vaccines including
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000007792 addition Methods 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
peptídeos de c18orf54 e vacinas incluindo os mesmos. a presente invenção refere-se a vacinas de peptídeo contra câncer que são descritas aqui. em particular, peptídeos de peptídeo contra câncer que são descritas aqui. em particular, peptídeos de epítopo isolados ou fragmentos imunogênicos derivados de seq id no:35, que se ligam a um antigeno hla e induzem linfócitos t citotóxicos (clt) são providos. as semodificadas com a substituição, deleção, inserção ou adição de uma, duas ou várias sequências de aminoácido. composições farmacêuticas e métodos de tratamento de câncer que incluem tais peptídeos são também providos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40548610P | 2010-10-21 | 2010-10-21 | |
PCT/JP2011/005844 WO2012053200A1 (en) | 2010-10-21 | 2011-10-19 | C18orf54 peptides and vaccines including the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013009276A2 true BR112013009276A2 (pt) | 2019-09-24 |
Family
ID=45974930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013009276A BR112013009276A2 (pt) | 2010-10-21 | 2011-10-19 | peptídeos de c18orf54 e vacinas incluindo os mesmos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20130287805A1 (pt) |
EP (1) | EP2630237A4 (pt) |
JP (1) | JP2014500001A (pt) |
KR (1) | KR20130138803A (pt) |
CN (1) | CN103282494B (pt) |
AU (1) | AU2011319353A1 (pt) |
BR (1) | BR112013009276A2 (pt) |
CA (1) | CA2815100A1 (pt) |
IL (1) | IL225553A0 (pt) |
MX (1) | MX2013004416A (pt) |
RU (1) | RU2013123038A (pt) |
SG (1) | SG189278A1 (pt) |
TW (1) | TW201300423A (pt) |
WO (1) | WO2012053200A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014041784A1 (en) | 2012-09-11 | 2014-03-20 | Oncotherapy Science, Inc. | Ube2t peptides and vaccines containing the same |
DK3573600T3 (da) | 2017-01-25 | 2022-05-09 | Ose Immunotherapeutics | Fremgangsmåde til fremstilling af en stabil emulsion til peptidlevering |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004018667A1 (ja) * | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ペプチド及びこれを含む医薬 |
EP2298895A1 (en) * | 2005-07-27 | 2011-03-23 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
RU2009114745A (ru) * | 2006-09-19 | 2010-10-27 | Новартис АГ (CH) | Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования |
CA2689974A1 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
GB0904957D0 (en) * | 2009-03-23 | 2009-05-06 | Univ Erasmus Medical Ct | Tumour gene profile |
-
2011
- 2011-10-19 KR KR1020137012777A patent/KR20130138803A/ko not_active Application Discontinuation
- 2011-10-19 SG SG2013025408A patent/SG189278A1/en unknown
- 2011-10-19 RU RU2013123038/10A patent/RU2013123038A/ru not_active Application Discontinuation
- 2011-10-19 AU AU2011319353A patent/AU2011319353A1/en not_active Abandoned
- 2011-10-19 CA CA2815100A patent/CA2815100A1/en not_active Abandoned
- 2011-10-19 TW TW100137832A patent/TW201300423A/zh unknown
- 2011-10-19 EP EP11834046.2A patent/EP2630237A4/en not_active Withdrawn
- 2011-10-19 MX MX2013004416A patent/MX2013004416A/es unknown
- 2011-10-19 WO PCT/JP2011/005844 patent/WO2012053200A1/en active Application Filing
- 2011-10-19 US US13/880,632 patent/US20130287805A1/en not_active Abandoned
- 2011-10-19 CN CN201180061391.2A patent/CN103282494B/zh not_active Expired - Fee Related
- 2011-10-19 BR BR112013009276A patent/BR112013009276A2/pt not_active IP Right Cessation
- 2011-10-19 JP JP2013518613A patent/JP2014500001A/ja not_active Withdrawn
-
2013
- 2013-04-04 IL IL225553A patent/IL225553A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20130138803A (ko) | 2013-12-19 |
WO2012053200A1 (en) | 2012-04-26 |
EP2630237A1 (en) | 2013-08-28 |
AU2011319353A1 (en) | 2013-06-13 |
MX2013004416A (es) | 2013-10-01 |
CN103282494B (zh) | 2015-06-17 |
US20130287805A1 (en) | 2013-10-31 |
EP2630237A4 (en) | 2014-04-09 |
RU2013123038A (ru) | 2014-11-27 |
IL225553A0 (en) | 2013-06-27 |
SG189278A1 (en) | 2013-05-31 |
CN103282494A (zh) | 2013-09-04 |
CA2815100A1 (en) | 2012-04-26 |
JP2014500001A (ja) | 2014-01-09 |
TW201300423A (zh) | 2013-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011011132A (es) | Peptido auxiliar del antigeno del cancer. | |
UA103751C2 (ru) | Иммуногенный пептид для иммунотерапии | |
NZ733168A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
EP3533461A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
EP3412304A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
EA200870237A1 (ru) | Последовательности пептидов и композиции | |
MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
DK2280721T3 (da) | Indoleamin-2, 3-dioxygenasebaseret immunterapi | |
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
MX2023014457A (es) | Peptidos antigenicos para la prevencion y el tratamiento del cancer. | |
NZ708990A (en) | Method for activating helper t cell | |
PE20181897A1 (es) | Inmunoterapia contra el melanoma y otros tipos de cancer | |
NZ609916A (en) | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
MX355054B (es) | Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo. | |
BR112016012306A2 (pt) | peptídeos ricos em prolina para proteção contra s. pneumoniae | |
MX355759B (es) | Peptidos topk y vacunas que incluyen los mismos. | |
BR112012018457A2 (pt) | peptídeos melk modificados e vacinas contendo os mesmos | |
MY166516A (en) | Tomm34 peptides and vaccines including the same | |
MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
EP3868778A3 (en) | Cdc45l peptides and vaccines including the same | |
BR112013009276A2 (pt) | peptídeos de c18orf54 e vacinas incluindo os mesmos | |
MX2011004176A (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. | |
BR112013009526A2 (pt) | peptídeos de wdhd1 e vacinas incluindo os mesmos | |
BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |